Singapore markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.6300-0.0100 (-0.22%)
At close: 04:00PM EST
4.7000 +0.07 (+1.51%)
After hours: 07:53PM EST
Sign in to post a message.
  • B
    BagholderHumper
    BAGHOLDERS can read'em and WEEP -- NEW SCRIPT NUMBERS:

    Week ending 11/12/2021

    TRx 697 vs 788
    TRx $1.47mm vs $1.59mm

    NRx 277 vs 324
    NRx $611.96k vs $626.03k

    Refills 420 vs 464

    ROFLMAO!!!
  • H
    Home Biscuit
    Just got a job in a mirror factory..........

    it's work I can see myself doing.
  • H
    Harry
    Keep in mind that afrezza was approved more than 7 years ago. New =324 Refill = 464. A massive flop. Remember #mnkd net loss increased 71% while # of shares went up by 14%
  • M
    MARTIN
    Wow! New scripts for week that ended 11/12/2021= 277 that's down 14.5% from previous week and refills at 420 are down by 9.48%. Not good. Not good at all!!
  • M
    MARTIN
    The short sale volume percent (not short interest) for stock ticker MNKD is 41% on Nov 23, 2021. The short sale volume percent is up 7% compare to Nov 22, 2021.
  • M
    MARTIN
    The short sale volume percent (not short interest) for stock ticker MNKD is 40% on Nov 12, 2021.
  • B
    BlueMan
    Net revenue per employee is -241519.0. NEGATIVE $241519 per employee.
    And this from 3Q21 SEC 10Q filing: The net loss for the nine months ended September 30, 2021 was $52.9 million, or $0.21 per share, compared to a $30.8 million net loss in the nine months ended September 30, 2020, or $0.14 per share.
  • A
    Anonymous
    LOL MORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that YUTREPIA has met all regulatory standards for quality, safety and efficacy required for approval in the United States.
  • M
    MARTIN
    The short sale volume percent (not short interest) for stock ticker MNKD is 40% on Nov 15, 2021
  • H
    Harry
    Only things that matters is script numbers for their one and only drug Afrezza. New =324 Refill = 464.
    Keep in mind that afrezza was approved more than 7 years ago. Remember #mnkd net loss increased 71% while # of shares went up by 14%
  • H
    Harry
    All that matters are Afrezzy script numbers and they were horrific for the week ending October 29. Total New 298
    total refill 416
  • m
    me2Sach
    Afreza, only product of this decades old company, is a flop of a lifetime.
  • P
    Paul
    LQDA won 7 of 9 patent challenges against $uthr treprostinil. The 2 remaining are both of which require actual storage at ambient temperature of treprostinil sodium. The PTAB’s decision primarily relates to the issue of patentability based on a review of prior art. This decision does not preclude the invalidation of the remaining claims on other grounds as part of the ongoing Hatch Waxman litigation, nor does it mean that Liquidia infringes either of the surviving claims.

    Damian deGoa, President and Chief Executive Officer of Liquidia said: “We are very pleased with this decision by the PTAB. This is a clear win in our on-going patent dispute with United Therapeutics, and we remain confident that we will ultimately prevail on all patent claims they have asserted against us. We will continue to vigorously defend our right to commercialize LIQ861 as soon as possible.”
  • j
    john
    About clofazimine : Novartis was only pharma that tried to sell this 70 yr old drug. They stopped marketing it and dumped it. Clofazimine has monstrous adverse side effects -- suicides, heart conditions, horrific skin conditions that have been known to remain for several years after using the drug and the drug crystalizing in the user’s body and clogging various organs requiring surgery.
  • A
    Anonymous
    Affrezza dpi shows the utter failure of technosphere. Just look at terrible script numbers. Tyvasso(treprostinil) dpi technosphere just got a CRL ( rejection) from FDA. Don't forget that $LQDA Receives Favorable Ruling in Inter Partes Review against United Therapeutics $UTHR Patent of treprostinil inhalation .
  • M
    Mango
    $UTHR conversation
    $mnkd drug Afrezza was approved 7 years ago. It's the lone drug that uses $mnkd's stone age delivery system called technosphere. It is a flop of historic proportions. Look no further than the terrible script numbers for afrezza in the giant diabetes market - New scripts 298 and refills 416 for week ending 10/29/2021. MNKD a failure in diabetes, will be a failure in pah market. Time for UTHR to cut their losses.
  • N
    Nomdguer
    Remember, UTHR has a treprostinil pill. $UTHR admits loads of pah drugs being marketed. UTHR has lost treprostinil patent lawsuits. UTHR's future is with their over $1,200,000,000 oral ralinepeg pill. While they have no piece of MNKD stock, They did buy a stake in a private pharma that has cutting edge transdermal pah technology and are working heavily with them. They know how old mnkd tech is and how big a flop the only drug that has used technosphere in 28yrs is. Wonder how happy $uthr is about losing the Inter Partes Review of treprostinil Patent to $LQDA and throwing away $105MM for an accelerated FDA review voucher for Tyvaso DPI only to get rejected CRL by FDA.
  • B
    Blueman
    ✅Vertice Pharma partnership cancelled. ✅No sales of Afrezza in Brazil since Biomm bought $200K in 2Q2020. ✅Afrezza Australia partnership terminated ✅Net loss up 71%✅#of shares go up 14%
  • m
    me2Sach
    mnkd great at diluting shares and accumulating debt. Longy's scared period.
  • B
    BlueMan
    Here's why not to buy or to sell or short MNKD
    Reason #32 - AFREZZA causes a decline in lung function over time as measured by FEV1. (source FDA)
    Reason #33 - AFREZZA provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. More subjects in the insulin aspart group achieved the HbA1c target of ≤7%. ( source FDA )